ADMA Test · Blood

Your blood vessels depend on a gas called nitric oxide to stay open, flexible, and responsive. When something interferes with nitric oxide production, your vessels stiffen, blood pressure rises, and the conditions for heart attack, stroke, and kidney failure quietly take hold. ADMA (asymmetric dimethylarginine) is the molecule your body uses to dial down nitric oxide, and when it builds up too high, the damage accumulates long before you feel anything.

What makes this test valuable is that ADMA rises in people whose standard labs look perfectly clean. Young adults with high cholesterol but no symptoms already show ADMA levels more than double those of matched controls, along with measurable impairment in how their blood vessels relax. A normal lipid panel, blood pressure reading, or kidney function test does not tell you whether your nitric oxide system is under stress. ADMA does.

How ADMA Works in Your Body

ADMA is created when your body breaks down proteins that have been chemically modified by enzymes called protein arginine methyltransferases (PRMTs). As these modified proteins are recycled, free ADMA is released into your bloodstream. Once circulating, ADMA competes with L-arginine (the raw material for nitric oxide) at the enzyme that produces nitric oxide, called nitric oxide synthase (NOS). The more ADMA present, the less nitric oxide your vessels can make.

But ADMA does more than just reduce nitric oxide. At high concentrations, it can cause the nitric oxide enzyme itself to malfunction, a process scientists call "uncoupling." Instead of producing protective nitric oxide, the enzyme starts generating superoxide, a damaging molecule that accelerates the wear and tear inside your arteries. This has been directly demonstrated in human blood vessels taken from patients undergoing heart surgery.

Your body clears ADMA primarily through an enzyme called DDAH (dimethylarginine dimethylaminohydrolase), which breaks it down into harmless byproducts. A smaller amount is filtered out by the kidneys. Anything that impairs DDAH activity or kidney function can cause ADMA to accumulate.

Heart Disease and Cardiovascular Events

The link between ADMA and heart disease is among the most consistent findings in cardiovascular biomarker research. A meta-analysis pooling 22 prospective studies found that people in the highest third of ADMA had about 40% higher risk of cardiovascular events, including heart attacks and strokes, compared to those in the lowest third. A separate meta-analysis focused on all-cause mortality found a roughly 50% higher risk of death from any cause for those with the highest ADMA levels, a finding that held even in people without pre-existing heart or kidney disease.

In a community-based study of about 3,300 adults followed for approximately 11 years, higher ADMA predicted death from all causes even after adjusting for standard risk factors and other biomarkers. The signal was especially strong in people without diabetes. When ADMA was infused directly into healthy volunteers in a controlled experiment, it acutely raised blood pressure, increased the resistance in their blood vessels, and reduced the heart's pumping efficiency, confirming that ADMA is not just a bystander marker but an active driver of cardiovascular stress.

Among patients referred for coronary angiography (a procedure to look at heart arteries), those in the highest quarter of ADMA had roughly 80 to 90% higher risk of cardiovascular and total death compared to the lowest quarter. After a heart attack, ADMA measured at admission strongly predicted who would die within the following year, beyond what traditional risk factors and other cardiac biomarkers could tell.

Kidney Disease

Because the kidneys help clear ADMA, kidney disease and ADMA levels are tightly linked. In patients with chronic kidney disease (CKD), ADMA rises as kidney filtration declines and independently predicts who will progress to dialysis or die. In one landmark study of 225 patients with end-stage kidney disease, ADMA was a strong and independent predictor of both overall mortality and cardiovascular outcomes.

ADMA also predicts the progression of coronary artery calcification, the buildup of calcium deposits in heart arteries, specifically in CKD patients. In kidney transplant recipients, elevated ADMA was associated with worse graft survival, more cardiovascular events, and higher mortality. If you have any degree of kidney impairment, ADMA adds information that creatinine and eGFR (estimated glomerular filtration rate, a standard measure of kidney function) alone do not capture.

Stroke, Cognitive Decline, and Dementia

ADMA has been linked to cerebrovascular disease in multiple studies. In a Swedish population study, ADMA was a strong marker for transient ischemic attack (TIA, sometimes called a "mini-stroke") and was elevated in acute stroke patients. A meta-analysis of circulating arginine-related molecules found that both ADMA and its sibling molecule SDMA (symmetric dimethylarginine) were significantly higher in people with Alzheimer's disease and vascular dementia compared to healthy controls.

The connection makes biological sense: nitric oxide is essential for maintaining blood flow to the brain, and chronic nitric oxide deficiency from elevated ADMA could contribute to the small-vessel damage that underlies both stroke risk and cognitive decline over decades.

Metabolic Health and Insulin Resistance

ADMA levels climb in step with metabolic risk factors. In a study of nearly 3,000 adults, ADMA was associated with obesity-related insulin resistance, the condition in which your cells stop responding normally to insulin. ADMA levels are highest in people who carry the most cardiovascular risk factors: hypertension, diabetes, and high cholesterol together. In a study of about 140 adults, those with all three conditions had the highest ADMA concentrations, while those with no risk factors had the lowest.

ADMA vs. SDMA: Two Related but Different Tests

ADMA and SDMA (symmetric dimethylarginine) are often discussed together, and the test panel on this site reports both. They share a similar molecular structure but work differently. ADMA directly blocks nitric oxide production. SDMA does not block the enzyme directly but instead interferes with the transport of L-arginine into cells, indirectly reducing nitric oxide availability. SDMA is cleared almost entirely by the kidneys, making it a particularly strong marker of kidney function.

In some settings, especially non-dialysis CKD, SDMA may actually outperform ADMA as a predictor of kidney disease progression and cardiovascular events. The two markers complement each other: ADMA reflects the state of your nitric oxide system and vascular health broadly, while SDMA adds information about how well your kidneys are clearing waste.

When Results Can Be Misleading

ADMA is relatively stable day to day in healthy people, with a within-person variation of about 7.4% from week to week. That tight control means a genuine change of at least 20% between two draws is needed before you can be confident the shift is real rather than normal biological fluctuation. A few situations can push your result in a misleading direction.

• Acute illness or hospitalization: Severe infections, sepsis, organ failure, and acute heart attacks can spike ADMA dramatically. A reading taken during or shortly after a serious illness reflects acute stress, not your baseline vascular health. Wait until you have fully recovered before testing.
• Kidney impairment: Because the kidneys help clear ADMA, even moderate kidney dysfunction raises levels. If your eGFR is reduced, your ADMA will be higher partly because of impaired clearance, not solely because of worse vascular health. Interpret the number alongside your kidney function.
• Liver dysfunction: The DDAH enzyme that breaks down ADMA is concentrated in the liver. Liver disease reduces DDAH activity, causing ADMA to accumulate. If you have known liver problems, discuss this with your physician when interpreting results.
• Assay method differences: Labs using different testing technologies tend to report slightly different values. Do not compare numbers across labs or methods. Stick with one lab for serial tracking.

Tracking Your Trend

A single ADMA reading gives you a snapshot, but serial measurements tell a story. Because ADMA sits in a narrow physiological range, even a modest upward drift over months or years can signal worsening vascular health before you develop symptoms or before standard tests like cholesterol or blood pressure change.

The biological variation data support this approach. ADMA's week-to-week fluctuation in healthy people is small (about 7%), which means your individual baseline is fairly stable. If you see your number creep from 0.50 to 0.65 over a year, that represents a real biological shift worth investigating, not just noise. Get a baseline reading, retest in 3 to 6 months if you are making lifestyle or treatment changes, and then at least annually.

Because ADMA responds to some interventions (statins, for example, have been shown to lower it in meta-analyses), serial tracking also lets you measure whether a change you have made is actually working at the vascular level, not just improving a cholesterol number on paper.

What to Do With an Elevated Result

If your ADMA comes back in the upper normal or elevated range, the first step is to confirm it with a second draw under the same conditions (fasting, morning, same lab). Rule out transient causes: recent illness, dehydration, or acute stress. Once confirmed, consider the clinical context.

• Check kidney and liver function: Order eGFR, cystatin C, and liver enzymes (ALT, AST, GGT) if not recently done. Impaired clearance organs can drive up ADMA independently.
• Assess cardiovascular risk comprehensively: Pair ADMA with ApoB (apolipoprotein B, the best single measure of atherogenic particle burden), hs-CRP (high-sensitivity C-reactive protein, a marker of systemic inflammation), homocysteine, and a standard lipid panel. A high ADMA alongside elevated ApoB and hs-CRP paints a much more urgent picture than any one of these alone.
• Consider a specialist: If ADMA is elevated alongside abnormal kidney function, a nephrologist can help. If it accompanies a cluster of cardiovascular risk markers, a cardiologist or lipidologist can guide treatment decisions.
• Address modifiable risk factors: High cholesterol, uncontrolled blood pressure, smoking, obesity, and poor metabolic health are all associated with higher ADMA. Treating these conditions with proven therapies (statins, blood pressure medications, weight loss) may lower ADMA over time.